147 related articles for article (PubMed ID: 8608982)
1. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis.
Seshadri R; Leong AS; McCaul K; Firgaira FA; Setlur V; Horsfall DJ
Int J Cancer; 1996 Apr; 69(2):135-41. PubMed ID: 8608982
[TBL] [Abstract][Full Text] [Related]
2. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer.
Iacopetta B; Grieu F; Powell B; Soong R; McCaul K; Seshadri R
Clin Cancer Res; 1998 Jul; 4(7):1597-602. PubMed ID: 9676832
[TBL] [Abstract][Full Text] [Related]
3. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
4. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.
Bull SB; Ozcelik H; Pinnaduwage D; Blackstein ME; Sutherland DA; Pritchard KI; Tzontcheva AT; Sidlofsky S; Hanna WM; Qizilbash AH; Tweeddale ME; Fine S; McCready DR; Andrulis IL
J Clin Oncol; 2004 Jan; 22(1):86-96. PubMed ID: 14701769
[TBL] [Abstract][Full Text] [Related]
5. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
6. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
Seshadri R; Firgaira FA; Horsfall DJ; McCaul K; Setlur V; Kitchen P
J Clin Oncol; 1993 Oct; 11(10):1936-42. PubMed ID: 8105035
[TBL] [Abstract][Full Text] [Related]
8. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
9. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.
Nieto Y; Cagnoni PJ; Nawaz S; Shpall EJ; Yerushalmi R; Cook B; Russell P; McDermit J; Murphy J; Bearman SI; Jones RB
J Clin Oncol; 2000 May; 18(10):2070-80. PubMed ID: 10811672
[TBL] [Abstract][Full Text] [Related]
11. A simple index to predict prognosis independent of axillary node information in breast cancer.
Seshadri R; Horsfall DJ; McCaul K; Leong AS
Aust N Z J Surg; 1997 Nov; 67(11):765-70. PubMed ID: 9396991
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
13. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
15. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.
Cuny M; Kramar A; Courjal F; Johannsdottir V; Iacopetta B; Fontaine H; Grenier J; Culine S; Theillet C
Cancer Res; 2000 Feb; 60(4):1077-83. PubMed ID: 10706127
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg A; Tandon AK; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Killander D; McGuire WL
Cancer Res; 1990 Jul; 50(14):4332-7. PubMed ID: 1973070
[TBL] [Abstract][Full Text] [Related]
17. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
[TBL] [Abstract][Full Text] [Related]
18. Vimentin expression is not associated with poor prognosis in breast cancer.
Seshadri R; Raymond WA; Leong AS; Horsfall DJ; McCaul K
Int J Cancer; 1996 Jul; 67(3):353-6. PubMed ID: 8707408
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
[TBL] [Abstract][Full Text] [Related]
20. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
